Portfolio Companies News
May 22, 2018Nexstim Plc – first NBT® system ...
Company announcement, Helsinki, 22 May 2018, at 9:00 AM Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), the targeted neuromodulation company developing and commercializing its world-leading navigated non-invasive brain stimulation technology for therapeutic and diagnostic application... read more
May 17, 2018BioClin Therapeutics Announces Post...
(San Leandro, California, May 17, 2018) BioClin Therapeutics, Inc., a clinical stage drug development company announced today that data will be presented from its ongoing Phase 1b/2 study of B-701, a first-in-class anti-fibroblast growth factor receptor 3 (FGFR3) monoclonal antibody, plus docetax... read more
May 17, 2018BONESUPPORT creates its own US Comm...
Lund, Sweden, 08.45 CET, 17 May 2018 – BONESUPPORT HOLDING AB (publ) announces today that the current distribution agreement has been terminated and will be replaced by a network of independent distributors and its own commercial organization. This will allow BONESUPPORT to increase its marke... read more
May 16, 2018Onxeo Provides Business Update and ...
Development of lead product candidate, AsiDNA™, for the treatment of advanced solid tumors, progressing according to plan DRIIV phase I clinical trial ongoing Interim results expected in H2 2018 Cash position of €9.2 million at March 31, 2018, sufficient to support Company’s operati... read more
May 16, 2018Wilson Therapeutics AB (Publ) Inter...
JANUARY 1 – MARCH 31, 2018 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 68.9 M (loss: 31.4) Loss per share, before and after dilution, totaled SEK 2.43 (loss: 1.22) At March 31, cash and cash equivalents amounted to SEK 426.7 M (339.3) SIGNIFICANT EVENTS D... read more
May 02, 2018Q1 2018 General Market Overview
Since the start in 1996, HealthCap funds have invested in 110 portfolio companies.
41 of the portfolio companies have been taken public on nine different markets.
25 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 7 companies with a valuation of USD 1 billion or more and 35 companies with a valuation of SEK 1 billion or more.